{"title":"ru3 -适配体纳米粒子的自组装通过NADH的光氧化还原催化和溶酶体破坏引发焦亡","authors":"Shenting Zhang, Xufeng Zhu, Wenzhu Yu, Yunjiang Yu, Li qian, Zhikai Chen, Zitong Peng, Lijun Gao*, Lanmei Chen* and Jincan Chen*, ","doi":"10.1021/acs.jmedchem.5c0002210.1021/acs.jmedchem.5c00022","DOIUrl":null,"url":null,"abstract":"<p >Photodynamic therapy (PDT) can induce tumor cell death. <b>Ru3</b>, a metal-based photosensitizer, features a high positive charge, a long triplet excited-state lifetime, and an excellent PDT activity. The aptamer AS1411, known for its ability to selectively bind to nucleolin (which is overexpressed in tumor cells), self-assembled with <b>Ru3</b> into nanoparticles termed <b>Ru3ApNPs</b>. These nanoparticles specifically target SiHa tumor cells. Upon light irradiation, <b>Ru3ApNPs</b> increase intracellular ROS levels, catalyze NADH redox reactions, and induce lysosomal disruption, ultimately triggering pyroptosis in tumor cells. Notably, <b>Ru3ApNPs</b> demonstrate excellent tumor penetration in 3D multicellular spheroids (MCSs) of SiHa cells and effectively inhibit their growth under light exposure. <b>Ru3ApNPs</b> exhibit a mechanism of action distinct from that of traditional PDT. Furthermore, under light irradiation, <b>Ru3ApNPs</b> can effectively inhibit the growth of distant tumors and induce systemic immune responses in mice. Our data suggest that <b>Ru3ApNPs</b> can be developed as promising targeted therapeutic agents in the future.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 11","pages":"11017–11038 11017–11038"},"PeriodicalIF":6.8000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Self-Assembly of Ru3-Aptamer Nanoparticles Triggers Pyroptosis through Photoredox Catalysis of NADH and Lysosomal Disruption\",\"authors\":\"Shenting Zhang, Xufeng Zhu, Wenzhu Yu, Yunjiang Yu, Li qian, Zhikai Chen, Zitong Peng, Lijun Gao*, Lanmei Chen* and Jincan Chen*, \",\"doi\":\"10.1021/acs.jmedchem.5c0002210.1021/acs.jmedchem.5c00022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Photodynamic therapy (PDT) can induce tumor cell death. <b>Ru3</b>, a metal-based photosensitizer, features a high positive charge, a long triplet excited-state lifetime, and an excellent PDT activity. The aptamer AS1411, known for its ability to selectively bind to nucleolin (which is overexpressed in tumor cells), self-assembled with <b>Ru3</b> into nanoparticles termed <b>Ru3ApNPs</b>. These nanoparticles specifically target SiHa tumor cells. Upon light irradiation, <b>Ru3ApNPs</b> increase intracellular ROS levels, catalyze NADH redox reactions, and induce lysosomal disruption, ultimately triggering pyroptosis in tumor cells. Notably, <b>Ru3ApNPs</b> demonstrate excellent tumor penetration in 3D multicellular spheroids (MCSs) of SiHa cells and effectively inhibit their growth under light exposure. <b>Ru3ApNPs</b> exhibit a mechanism of action distinct from that of traditional PDT. Furthermore, under light irradiation, <b>Ru3ApNPs</b> can effectively inhibit the growth of distant tumors and induce systemic immune responses in mice. Our data suggest that <b>Ru3ApNPs</b> can be developed as promising targeted therapeutic agents in the future.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 11\",\"pages\":\"11017–11038 11017–11038\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00022\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00022","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Self-Assembly of Ru3-Aptamer Nanoparticles Triggers Pyroptosis through Photoredox Catalysis of NADH and Lysosomal Disruption
Photodynamic therapy (PDT) can induce tumor cell death. Ru3, a metal-based photosensitizer, features a high positive charge, a long triplet excited-state lifetime, and an excellent PDT activity. The aptamer AS1411, known for its ability to selectively bind to nucleolin (which is overexpressed in tumor cells), self-assembled with Ru3 into nanoparticles termed Ru3ApNPs. These nanoparticles specifically target SiHa tumor cells. Upon light irradiation, Ru3ApNPs increase intracellular ROS levels, catalyze NADH redox reactions, and induce lysosomal disruption, ultimately triggering pyroptosis in tumor cells. Notably, Ru3ApNPs demonstrate excellent tumor penetration in 3D multicellular spheroids (MCSs) of SiHa cells and effectively inhibit their growth under light exposure. Ru3ApNPs exhibit a mechanism of action distinct from that of traditional PDT. Furthermore, under light irradiation, Ru3ApNPs can effectively inhibit the growth of distant tumors and induce systemic immune responses in mice. Our data suggest that Ru3ApNPs can be developed as promising targeted therapeutic agents in the future.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.